
Recent Advances in Directed Protein Evolution



Hui-Wen Shih

October 19, 2011

Lin, H.; Cornish, V. W. Angew. Chem. Int. Ed. 2002, 41, 4402.

Yuan, L.; Kurek, I.; English, J.; Keenan, R. Microbiol. Mol. Biol. Rev. 2005, 69, 373.

Turner, N. J. Nat. Chem. Biol. 2009, 5, 567.


If you could design a protein...

...why would you do it?

...what would it do?

Protein Design

Develop novel catalysts to access unknown transformations



Improve upon existing catalysts

Thermostability Solvent tolerance pH tolerance Increased activity/selectivity Expand substrate scope

Develop novel biological tools

Probe mechanism and structure

Improve upon rational design

Understand natural protein evolution


If you could design a protein...

...why would you do it?


...what would it do?

...how would you do it?

Evolution: A Nature-Inspired Strategy




Directed protein evolution is a protein engineering strategy that harnesses the power of natural selection to evolve proteins with desirable functions.



Why Directed Evolution?


- Currently, we cannot accurately tailor proteins for a specific purpose using rational design
- There are too many possibilities to generate and search all of them



100 amino acids long


20¹⁰⁰ possibilities

By imposing selection pressures, iterative rounds of evolution will naturally select for best players



A Bit of History

1973 - Campbell, Lengyel and Langridge uses directed evolution to discover a novel β-galactosidase




encoded by *lacZ* in *E. coli*


metabolizes lactose

allows for growth on lactose medium

After *lacZ* deletion, a new β -galactosidase is evolved




How It Works



Jackel, C.; Kast, P.; Hilvert, D. Annu. Rev. Biophys. 2008, 37, 153.

Biochemistry: A Few Notes



Biology: A Few Notes

What you need to know about phages

bacteriophage

pIII

<u>leen</u>


phages display pIII on the surface

pIII is required to infect bacteria

What you need to know about bacteria



bacteria can carry multiple plasmids



plasmids contain genetic material


plasmids are widely used to introduce new genes in bacteria (transform)


engineered to confer specific traits

Creating Diversity


■ Polymerase Chain Reaction (PCR) allows for rapid genetic amplification








Mutations during PCR generates a genetic library



Creating Diversity

Recombination/DNA shuffling generates more libraries with more working proteins



Mutations and recombinations also occur in vivo



Screening and Selecting for Desired Function

Assays must accomplish the following


Link genotype with phenotype

Allow for genetic amplification


Screen individuals rapidly

Caution: you get what you screen for!

Microtiter plates



each well contains a different gene mutation




each well contains a corresponding protein

Typical assays GC/HPLC UV-Vis radioactivity fluorescence

Screening and Selecting for Desired Function

mRNA display physically links phenotype and genotype using puromycin




During translation, ribosome pauses at the DNA spacer, allowing puromycin to react with peptide chain


Screening and Selecting for Desired Function

In vivo selection - desired function is linked to survival

eg. antibiotic resistance, replication ability, metabolism ability...



How It Works




Jackel, C.; Kast, P.; Hilvert, D. Annu. Rev. Biophys. 2008, 37, 153.

analyze/characterize


PACE: A System for Continuous Directed Evolution

Design T7 RNA polymerase to recognize a new promoter sequence



Bacteriophage RNA polymerase Widely used to transcribe RNA *in vitro* and *in vivo* Very specific for promoter sequence


Strategy: link phage survival (pIII expression) with activity of T7 RNA polymerase



PACE: A System for Continuous Directed Evolution


Host cells continuously flow through lagoon faster than they can replicate

inflow of host cells




PACE: A System for Continuous Directed Evolution

Selection pressure becomes more stringent over time




■ Januvia (sitagliptin phosphate) is a blockbuster drug




Treatment of diabetes DPP-IV inhibitor

#24 brand name drug in 2010 \$1,294M


Previous manufacture route to set amine stereocenter




- 1. NH₄OAc
 2. Rh[Josiphos]/H₂ (250 psi)
 3. Remove Rh
- 4. Recrystallize (from 97% e.e.)



Desired reactivity




A computational approach in silico rational design



Transaminase ATA-117 (dimer) Small and large binding pockets identified Docking studies shows binding pocket is too small Residues in active site identified for mutation






Savile, C. K. et. al. Science 2010, 329, 305.

Improvements on original process route

1. NH₄OAc

- 2. Rh[Josiphos]/H₂ (250 psi)
- 3. Remove Rh
- 4. Recrystallize (from 97% e.e.)



Improvements

10-13% yield increase

53% productivity increase (kg/l/day)


19% total waste reduction

no heavy metals

no high-pressure equipment

Savile, C. K. et. al. Science 2010, 329, 305.


Mutations reflect contribution from in silico modeling



Final catalyst has 27 mutations


10 mutations: noncatalytic AA interacting with substrate
4 mutations: design of small binding pocket
5 mutations: evolution of large binding pocket
1 mutation: evolution of small binding pocket
10 mutations: homology libraries
5 random mutations

Later improvements modify the dimer interfacial region, persumably leading to more stable active dimer



Savile, C. K. et. al. Science 2010, 329, 305.


The World Health Organization: HIV is a pandemic



- 0.6% of the world population is infected
- 13 of the best 200 drugs (2010) are for HIV therapies
- Combined sales of \$4.7 billion
- No cure


Njardson Group, http://cbc.arizon.edu/njardarson/group/top-pharmaceuticals-poster

Evolution of a HIV-1 DNA exicision enzyme




HIV-1 proviral DNA is flanked by long terminal repeats (LTRs)

Cre recombinase is a bacteriophage topoisomerase



recognizes 34 bp loxP site

removes sequences flanked by two loxP sites




■ loxLTR sequence chosen as recognition target has 50% sequence similarity with *loxP*


ATAACTTCGTATA ATGTATGC TATACGAAGTTAT LoxP

ACAACATCCTATT ACACCCTA TATGCCAACATGG LoxLTR


■ loxLTR sequence shows high sequence similarity to other HIV-1 LTRs




After 126 rounds of evolution, Tre is identified as the most active recombinase with 19 amino acid changes



Tre is inserted into mammalian HeLa cells with HIV promoter (Tat)






Tre works only if two loxLTR sites are present

T1 = 1 loxLTR site T2 = 2 lox LTR sites


Tre is inserted into HeLa cells and cells are infected with HIV



Green = gag expressing cells (infected)


Blue = cell nucleus

Provirus is deleted from infected cells without obvious cytotoxicity




Evolving Activity: Zero to Hero

■ You get what you screen for!



Evolving Activity: Zero to Hero




Evolving Activity: Zero to Hero

2 % cDNA 1 immobilized 0 2 3 10 4 5 6 7 8 9 11 12 9 15* 10* 11* 12 13 4 16 60 min overnight 5 min reaction time


After 17 rounds of mutation, competent RNA ligase was evolved

Enzyme k_{obs} is 10⁶ times faster than uncatalyzed reaction




Modifying Nanoparticles

Capsids readily undergo modification for a variety of applications




gene therapy drug delivery bioimaging catalysis controlled synthesis


Protein capsid can be engineered to contain toxic materials



Modifying Nanoparticles

HIV expression is promoted by tetracycline






AaLS-13 has 7 point mutations No exterior modifications Addition of 3 anionic residues Loss of three cationic residues

- On average, each capsid can bind seven HIV protease-R₁₀ dimers
- 5-10 fold improvement results in cell survival even at 1400 ng/ml tetracyclin


-HIV prot.-R₁₀ +HIV prot.-R₁₀



dark interiors indicate prescence of protein

cryogenic electron micrograph





Natural amino acids are encoded with triplet codons

To encode unnatural amino acids, amber stop codon (UAG) is not read as stops in amber mutations


Artificial tRNAs recognize amber codon

Unnatural amino acid incorporation

is usually low (~20%)

Limited number of UAAs can be incorporated


Goal: Evolve orthogonal quadruplet-decoding ribosome



quadruplet codon recognition would allow multiple UAAs to be incorporated

in silico design combined with evolution starting from evolved orthogonal ribosome

Orthogonal ribosome (Ribo-x) recognizes orthogonal tRNA




ribo-X improves unnatural amino acid incorporation to >60%


127 sequences identified for mutation are highlighted in orange

11 saturation mutagenesis libraries created


selection is linked to chloramphenicol resistance

ribo-Q1 demonstrates best chloramphenicol resistance






Evolved ribosome recognizes both amber codon and AGGA quadruple codon





Glutathione-S-transferase (GST) and maltose-binding protein (MBP) fusion protein linked by codon for UAA

■ ribo-Q1 applied to novel protein synthesis




Glutathione-S-transferase-calmodulin fusion protein





GST-CaM 1 Tyr 149 CAK GST-CaM 1 AzPhe 149 CAK GST-CaM 1 AzPhe 149 BocK GST-CaM 1 AzPhe 40 CAK Click reagents

> GST-CaM-H₆ circ. GST-CaM-H₆



If you could design a protein...

...why would you do it?

...what would it do?